CW
Therapeutic Areas
Kesmalea Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Undisclosed Oncology Program(s) | Oncology | Preclinical |
| Undisclosed CNS Program(s) | Central Nervous System Disorders | Preclinical |
Leadership Team at Kesmalea Therapeutics
RJ
Robert Johnson
Chief Executive Officer
HF
Harry Finch
Chief Scientific Officer & Founder
MF
Mark Fox
Finance Director